Table 1.
Characteristics of included studies.
| Study | Age (years) | Sex (male/female) | ECOG performance status (0/≥1) | KRAS status (wild/mutated) | Methods | Sample | mOS (months) | mPFS (months) |
|---|---|---|---|---|---|---|---|---|
| Mayer et al. 2015 [4] | 63 (27-82) | 326/208 | 301/233 | 272/262 | TAS-102 | 534 | 7.1 (6.5-7.8) | 2 (1.9-2.1) |
| 63 (27-82) | 165/101 | 147/119 | 131/135 | Placebo | 266 | 5.3 (4.6-6.0) | 1.7 (1.7-1.8) | |
| Pfeiffer et al. 2020 [15] | 64 (57-69) | 24/22 | 23/23 | 19/27 | TAS-102+B | 46 | NA | 4.6 (3.5-6.5) |
| 67 (58-72) | 30/17 | 15/32 | 18/29 | TAS-102 | 47 | NA | 2.6 (1.6-3.5) | |
| Sueda et al. 2016 [16] | 66 (44-80) | 10/4 | 1/13 | 9/5 | TAS-102 | 14 | 6.3 (3.21-9.93) | 1 (0.92-6.39) |
| 59 (37-83) | 12/11 | 10/13 | 12/11 | REG | 23 | 5.8 (3.7-11.7) | 0 (1.64-4.52) | |
| Masuishi et al. 2017 [17] | NA | 30/24 | NA | 21/32 | TAS-102 | 54 | 6.5 (5.3-8.3) | 2.1 (1.8-3.1) |
| NA | 90/56 | NA | 78/67 | REG | 146 | 6.7 (5.8-7.6) | 2.1 (1.8-2.5) | |
| Makiyama et al. 2018 [18] | 66 (39-82) | 6/5 | 5/6 | NA | TAS-102+B | 11 | Not reached | 5.8 |
| 69 (47-82) | 20/13 | 11/22 | NA | TAS-102 | 33 | 6.4 | 1.8 | |
| Yoshino et al. 2012 [5] | 63 (28-80) | 64/48 | 72/40 | 54/45 | TAS-102 | 112 | 9.0 (7.3-11.3) | NA |
| 62 (39-79) | 28/29 | 35/22 | 24/26 | Placebo | 57 | 6.6 (4.9-8.0) | NA | |
| Cutsem et al. 2017 [9] | 60.2 (11.86) | 31/33 | 28/36 | 35/29 | TAS-102 | 64 | 6.5 | NA |
| 58.5 (11.02) | 18/17 | 13/22 | 17/18 | Placebo | 35 | 4.3 | NA | |
| 61.8 (9.98) | 167/104 | 138/133 | 123/148 | TAS-102 | 271 | NA | NA | |
| 62.1 (10.42) | 82/50 | 68/64 | 68/64 | Placebo | 132 | NA | NA | |
| 61.9 (10.09) | 113/65 | 128/50 | 94/84 | TAS-102 | 178 | 7.8 | NA | |
| 62.1 (10.40) | 58/30 | 60/28 | 40/48 | Placebo | 88 | 6.7 | NA | |
| Xu et al. 2017 [10] | 58 (26-81) | 170/101 | 64/207 | 172/99 | TAS-102 | 271 | 7.8 (7.1-8.8) | NA |
| 56 (24-80) | 84/51 | 30/105 | 85/50 | Placebo | 135 | 7.1 (5.9-8.2) | NA | |
| Longo-Muñoz et al. 2016 [19] | 5 (27-81) | 48/32 | 24/56 | 35/45 | TAS-102 | 80 | 6.8 | 2 |
| 5 (39-78) | 21/11 | 11/21 | 17/15 | Placebo | 32 | 4.6 | 1.7 | |
| Moriwaki et al. 2018 [20] | 64 (29-86) | 197/130 | 128/199 | 160/161 | TAS-102 | 327 | 7.4 (6.6-8.3) | NA |
| 64 (31-84) | 126/97 | 95/128 | 88/109 | REG | 223 | 7.9 (6.8-9.2) | NA | |
| Kotani et al. 2019 [21] | 60 (23-79) | 35/25 | 35/25 | 28/32 | TAS-102+B | 60 | 8.6 (6.9-10.3) | 3.7 (2.3-5.1) |
| 65 (30-80) | 42/24 | 42/24 | 30/36 | TAS-102 | 66 | 8.0 (6.7-9.4) | 2.2 (1.8-2.6) | |
| Fujii et al. 2020 [11] | 67 (50-74) | 13/8 | NA | 10/11 | TAS-102+B | 21 | 14.4 (7.9-NA) | NA |
| 67.5 (59.8-71.2) | 16/20 | NA | 16/20 | TAS-102 | 36 | 4.5 (3.2-6.5) | NA | |
| Ogata et al. 2020 [22] | 68 (40-85) | 38/39 | 35/42 | 53/24 | TAS-102 | 77 | 11.4 | 3.3 |
| 66 (41-81) | 30/27 | 30/27 | 36/21 | REG | 57 | 9.9 | 2 | |
| Nose et al. 2020 [23] | 73 (49-90) | 16/16 | 12/20 | 14/17 | TAS-102+B | 32 | 11.7 | 4.7 |
| 70.5 (43-88) | 15/9 | 7/17 | 14/10 | TAS-102 | 24 | 6.3 | 1.8 | |
| Cicero et al. 2020 [24] | 78 (70-86) | 28/22 | 18/32 | 18/22 | TAS-102 | 50 | 6.7 (5.7-11.3) | 2.1 (1.2-3.2) |
| Cecchini et al. 2021 [25] | NA | NA | NA | NA | TAS-102 | 41 | 6.8 (5.7-10) | 2.7 (2.4-4.8) |
| Sforza et al. 2017 [26] | 65 (48-82) | 31/12 | 27/16 | 16/27 | TAS-102 | 43 | 6.6 (2.8-10.4) | 2.8 (2.5-3.1) |
| Montes et al. 2020 [27] | 63 (37-83) | 108/52 | 18/142 | 57/103 | TAS-102 | 160 | 7.64 (6.15-9.13) | 2.75 (2.57-2.94) |
| Takahashi et al. 2021 [28] | 73 (65-81) | 21/9 | NA | NA | TAS-102 | 30 | 5.7 (3.7-8.9) | 2.3 (1.9-4.3) |
| Kwakman et al. 2018 [29] | 62 (30-88) | 92/44 | 46/90 | 53/83 | TAS-102 | 136 | 5.4 (4.0-6.9) | 2.1 (1.8-2.3) |
| Moehler et al. 2021 [30] | 60 (35-78) | 6/6 | 6/6 | NA | TAS-102 | 12 | 11.1 (2.3-18.2) | 3.81 (1.51-5.29) |
| Yoshida et al. 2020 [31] | 67 (45-78) | 20/12 | 23/9 | 14/18 | TAS-102+B | 32 | 9.2 (5.5-12.8) | 4.5 (1.8-7.1) |
| Wallander et al. 2020 [32] | 65 (38-78) | 28/20 | 13/34 | 17/29 | TAS-102 | 48 | 6.4 (4.4-8.4) | 2.3 (1.8-2.7) |
| Satake et al. 2020 [33] | 69 (33-82) | 24/20 | 25/19 | 25/19 | TAS-102+B | 44 | 10.86 (8.32-13.68) | 4.29 (2.54-5.83) |
| Carries et al. 2019 [34] | 65.29 (40-88) | 49/35 | 13/71 | 31/53 | TAS-102 | 84 | 8.3 (6.23-9.87) | 2.62 (2.32-3.05) |